Filing Flows › Kura Oncology (KURA) › Q1 2025
Kura Oncology (KURA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Kura Oncology (KURA) reported revenue of $14.1M for the first quarter 2025 (Q1 2025). Operating margin was -458.6%, net loss $57.4M (407.1% of revenue).
Kura Oncology, Q1 2025: revenue $14.1M, operating margin -458.6%, net loss $57.4M, operating cash flow −$71.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.1M | — | — |
| Operating profit | −$64.7M | — | — |
| Net earnings | −$57.4M | — | — |
| Operating cash flow | −$71.9M | — | — |
What changed
Revenue was $14.1M in Q1 2025.
Operating costs exceeded revenue by $64.7M, an operating margin of -458.6%. The quarter ended with a net loss of $57.4M.
Operating cash flow was −$71.9M. Non-cash charges added back $241K of depreciation and $7.8M of share-based compensation. Working capital and other items used $22.6M. Capital expenditures of $292K exceeded it, leaving free cash flow of −$72.2M.
Questions
What was Kura Oncology's revenue in the first quarter 2025?
Kura Oncology (KURA) reported revenue of $14.1M for the first quarter 2025 (Q1 2025).
Was Kura Oncology profitable in the first quarter 2025?
Operating loss was $64.7M (-458.6% of revenue) and net loss $57.4M.
Source: Kura Oncology 10-Q on SEC EDGAR.